ERBB2 and breast carcinoma: HER2-enriched breast cancers initially respond to anti-HER2 antibodies such as Food and Drug Administration (FDA)-approved traustuzumab, lapatinib, pertuzumab, ado-trastuzumab emtansinse, and fam-trastuzumab (197–200), while TNBC patients have limited to no treatment options.